C3a, TNF-α and interleukin myocardial expression in a case of fatal sudden cardiac failure during clinic reactivation of systemic lupus erythematosus

Lupus

Volumn 19, Issue 10, 2010, Pages 1246-1249

  Pomara, C ^a   Neri, M ^a   Bello, S ^a   Pennella, A ^a   Turillazzi, E ^a   Fineschi, V ^a  

^a UNIVERSITY OF FOGGIA   (Italy)

Author keywords

C3a; sudden cardiac death; systemic lupus erythematosus; TNF

Indexed keywords

ANTIBIOTIC AGENT; ANTIBODY; ANTIPYRETIC AGENT; BICARBONATE; CD4 ANTIGEN; CD8 ANTIGEN; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C3A ANTIBODY; CYTOKINE; DOPAMINE; GLUCOCORTICOID; INTERLEUKIN 10 ANTIBODY; INTERLEUKIN 15 ANTIBODY; INTERLEUKIN 8 ANTIBODY; NORADRENALIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CASE REPORT; CAUCASIAN; DISEASE COURSE; ECHOCARDIOGRAPHY; ENDOCARDIUM; HEART FAILURE; HEART MUSCLE CELL; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MITRAL VALVE REGURGITATION; PERICARDIUM; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; SUDDEN DEATH; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; ANTIGENS, CD4; ANTIGENS, CD8; COMPLEMENT C3A; DEATH, SUDDEN, CARDIAC; HEART FAILURE; HUMANS; INTERLEUKINS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MYOCYTES, CARDIAC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77956252020     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203310367658     Document Type: Article

References (11)

1. Tseng CE, Buyon JP, Kim M., et al. The effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus. Findings of a prospective, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 1988 ; 31: 315-324.
2. Manson JJ, Rahman A. Systemic lupus erythematosus. Orphanet J Rare Dis 2006 ; 1: 6.
3. Clancy R., Marder G., Martin V., Belmont HM, Abramson SB, Buyon JP Circulating activated endothelial cells in systemic lupus erythematosus. Further evidence for diffuse vasculopathy. Arthritis Rheum 2001 ; 44: 1203-1208.
4. Murai K., Oku H., Takeuchi K., Kanayama Y., Inoue T., Takeda T. Alterations in myocardial systolic and diastolic function in patients with active systemic lupus erythematosus. Am Heart J 1987 ; 113: 966-971.
5. Riezzo I., Pomara C., Neri M., Turillazzi E., Fineschi V. Myocardial tumor necrosis factor-alpha expression in a sudden death due to dilated cardiomyopathy with endomyoelastofibrosis. Int J Cardiol 2009 ; 134: e62 - e65.
6. Frangogiannis NG, Wayne Smith C., Entman ML The inflammatory response in myocardial infarction. Cardiovasc Res 2002 ; 53: 31-47.
7. Usalan C., Buyukhatipoglu H., Tiryaki O. Systemic lupus erythematosus complicated by dilated cardiomyopathy and severe heart failure. Clin Rheumatol 2007 ; 26: 125-127.
8. Manzi S. Lupus update: perspective and clinical pearls. Clev Clin J Med 2009 ; 76: 137-142.
9. Turesson C., Jacobsson LTH, Matteson EL Cardiovascular co-morbidity in rheumatic disease. Vasc Health Risk Manag 2008 ; 4: 605-614.
10. Szekanecz Z., Shoenfeld Y. Lupus and cardiovascular disease: the facts. Lupus 2006 ; 15: 3-10.
11. Reynolds JA, Toescu V., Yee CS, Prabu A., Situnayake D., Gordon C. Effects of rituximab on resistant SLE disease including lung involvement. Lupus 2009 ; 18: 67-73.